Cleveland Clinic Taussig Cancer Institute
Avatar

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Available Therapy in Pts With MF Who Require RBC Transfusions

By Cleveland Clinic Taussig Cancer Institute FEATURING Aaron Gerds
By Cleveland Clinic Taussig Cancer Institute FEATURING Aaron Gerds
251 views
June 28, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Related Content

AUTOPLAY
24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
27:37
Indy Hematology Review

Review of Myeloproliferative Neoplasms

Feat. A. Tefferi
18:04
Ruben Mesa

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…

Feat. R. Mesa
18:42
Memorial Sloan Kettering Cancer Center

Key Updates in AML, MDS, & MF From ASH

Feat. A. Goldberg
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
24:48
Indy Hematology Review

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Feat. R. Rampal
11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Updates in Myeloproliferative Neoplasms

Feat. E. Hexner
31:43
Indy Hematology Review

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Feat. A. Tefferi
16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
17:23
Vanderbilt University Medical Center (VUMC)

Management of MF After Ruxolitinib Failure

Feat. A. Kishtagari
08:11
Krisstina Gowin

Counseling Patients With Newly Diagnosed PV or ET

09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
12:18
Fred Hutchinson Cancer Center

Management of MPNs for the Community Oncologist

Feat. H. Deeg
06:51
Insights from 2023 ASH Annual Meeting

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Feat. D. Tremblay
13:38
Insights from 2024 EHA Annual Meeting

Top 5 Impactful MPN Abstracts From Summer Conferences

Feat. P. Bose
11:03
Moffitt Cancer Center

Current Treatment Landscape of JAK Inhibitors in MF

Feat. A. Kuykendall